CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

Hansson, Oskar, Seibyl, John, Stomrud, Erik, Zetterberg, Henrik, Trojanowski, John Q., Bittner, Tobias, Lifke, Valeria, Corradini, Veronika +9 more·2018·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2018.01.010

Cited by (809)

Items 601–700 of 809

  1. Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
    Tanja Blume, Maximilian Deußing, Gloria Biechele, Finn Peters, Benedikt Zott, Claudio Schmidt, Nicolai Franzmeier, Karin Wind-Mark, Florian Eckenweber, Christian Sacher et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  2. Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A , and LILRB1 that associate with Alzheimer’s disease
    Joseph S. Reddy, Xue Wang, Mariet Allen, Minerva M. Carrasquillo, Joanna M. Biernacka, Gregory D. Jenkins, Brandon J. Coombes, Olivia Belbin, Todd Eliot Golde, Nilüfer Ertekin‐Taner et al. · 2022 · medRxiv
  3. CSF tau phosphorylation at T217 and T205 are improved biomarkers of amyloid and tau pathology in Alzheimer disease
    Nicolas R. Barthélemy, Benjamin A. Saef, Yan Li, Brian Andrew Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato et al. · 2022 · Research Square
  4. Risk of Alzheimer’s Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project Cohort
    Yian Gu, Lawrence S. Honig, Min Suk Kang, Aanya Bahl, Danurys L. Sanchez, Dolly Reyes‐Dumeyer, Jennifer Jaie Manly, Rafael Lantigua, Jeffrey L. Dage, Adam M. Brickman et al. · 2023 · medRxiv
  5. Five dominant dimensions of brain aging are identified via deep learning: associations with clinical, lifestyle, and genetic measures
    Zhijian Yang, Junhao Wen, Güray Erus, Sindhuja Tirumalai Govindarajan, Randa Melhem, Elizabeth Mamourian, Yuhan Cui, Dhivya Srinivasan, Ahmed Abdulkadir, Paraskevi Parmpi et al. · 2023 · medRxiv
  6. Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease
    Anika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, Olof T. Strandberg, Erik Stomrud, Niklas Mattsson, Shorena Janelidze, Ruben A Smith, Sebastian Palmqvist, Hannah Baumeister et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  7. A seven-year longitudinal study of the Alzheimer’s disease blood metabolome
    Bharadwaj Marella, Patrick Weinisch, Josef J. Bless, Shannon L. Risacher, Colette Blach, Naama Karu, Karel Kalecký, Tingting Wang, Kevin Huynh, Alexandra Kueider‐Paisley et al. · 2025 · medRxiv
  8. The fluid biomarkers of Alzheimer’s disease
    Qinyu Peng, Zhentao Zhang · 2021 · Brain Science Advances
  9. Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease
    Alexander Jethwa, Laura Stöckl · 2024 · Methods in molecular biology
  10. Cortical Thickness Correlates of Go/No-go and Motor Sequencing in Mild Cognitive Impairment and Suspected Alzheimer Disease Dementia
    Cierra M. Keith, Katharine E. Lindberg, Kirk C. Wilhelmsen, Rashi I. Mehta, Camila Vieira Ligo Teixeira, Mark D. Miller, Melanie Ward, Ramiro Osvaldo Navia, William Travis McCuddy, Liv E. Miller et al. · 2024 · Cognitive and Behavioral Neurology
  11. Diffusion MRI Allows Capturing the Amyloid-β and τ Proteins Status in Alzheimer’s Disease Continuum
    Giorgio Dolci, Federica Cruciani, Lorenza Brusini, Lorenzo Pini, Ilaria Boscolo Galazzo, Vince D. Calhoun, Gloria Menegaz · 2024 · IEEE International Symposium on Biomedical Imaging (ISBI)
  12. Interval-specific likelihood ratios and probability-based models for interpreting combined CSF biomarkers for Alzheimer’s disease
    Jonas Dubin, Rik R. Vandenberghe, Koen Poesen · 2024 · Clinica Chimica Acta
  13. Biomarkers for Alzheimer's Disease
    Deepak Panwar, Parul Sharma, Shweta Sharma, Manoj Malik, Jaspreet Kaur · 2024 · Advances in bioinformatics and biomedical engineering book series
  14. sTREM2 in discordant CSF Aβ42 and p‐tau181
    Danni Li, William G. Mantyh, Lu Men, Ishika Jain, Matthew Glittenberg, Binchong An, Lin Zhang, Ling Li, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  15. Evaluation of preanalytical factors on quantification of amyloid-β (1-42), phosphorylated tau 181, and total tau in cerebrospinal fluid
    Tiffany R Allison, Sonia L. La’ulu, Kelly J. Doyle, Heather A. Nelson · 2025 · Laboratory Medicine
  16. Comparison of diagnostic accuracy of Alzheimer's disease cerebrospinal fluid core biomarkers using INNOTEST, Lumipulse G, and Elecsys assays: Insights from the PUMCH dementia cohort study
    Chenhui Mao, Yutong Zou, Tianyi Wang, Longze Sha, Meiqi Wu, Shanshan Chu, Wei Jin, Bo Li, Yixuan Huang, Yuyue Qiu et al. · 2025 · Journal of Alzheimer s Disease
  17. Molecular pathways and biomarkers associated with age-related cognitive decline
    Shreyasi Mitra, Sampoorn Pandey, Aman Gill, Anannya Roy, Shibam Dutta, Amit Kumar, Majid Ali, Geetanjali Chawla · 2025 · Academia Biology
  18. Polygenic scores of Core 1 Alzheimer's disease biomarkers predict early cognitive and pathological change
    Yuexuan Xu, Min Qiao, Tamil Iniyan Gunasekaran, Yian Gu, Dolly Reyes‐Dumeyer, Angel L. Piriz, Danurys L. Sanchez, Belisa Soriano, Yahaira Franco, Zoraida Dominguez Coronado et al. · 2025 · Alzheimer s & Dementia
  19. The Utility of CSF Biomarkers in Diagnosing Alzheimer’s Disease: A Thai Cohort Study
    Witsarut Nanthasi, Chatchawan Rattanabannakit, Natthamon Wongkom, Pathitta Dujada, Atthapon Raksthaput, Sunisa Chaichanettee, Paphawadee Phoyoo, Leatchai Wachirutmanggur, Seong Soo A. An, Vorapun Senanarong · 2025 · Dementia and Geriatric Cognitive Disorders Extra
  20. Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217
    Aleix Martí Navia, Lourdes Álvarez‐Sánchez, Laura Ferré‐González, Alejandro López, Carmen Peña‐Bautista, Ángel Balaguer, N. Risueño Pedrosa, Helena Vico, Miguel Baquero, Consuelo Cháfer‐Pericás · 2025 · Scientific Reports
  21. In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer’s disease continuum
    Douglas Teixeira Leffa, Guilherme Povala, Pâmela C.L. Ferreira, João Pedro Ferrari‐Souza, Guilherme Bauer‐Negrini, Matheus Scarpatto Rodrigues, Lívia Amaral, Firoza Zubeida Lussier, Marina Scop Medeiros, Carolina Soares et al. · 2025 · Molecular Psychiatry
  22. The biomarker and clinical changes across the Alzheimer’s continuum study (BCAS): rationale, design, and baseline characteristics of the first 1,013 participants
    Hui Chen, Hong Dai, L D Zhang, Yongjian Deng, Kan Zhang, Jie Yu, Guoping Peng, Zexin Guo, Jing Zhang, Changzheng Yuan et al. · 2025 · Alzheimer s Research & Therapy
  23. The capacity for Alzheimer's disease confirmatory testing in the United States: The current situation and simulations for future increase
    Sophie Roth, Jessie T. Yan, Maria-Magdalena Patru, Soeren Mattke, Anders Gustavsson, Gustaf Ortsäter · 2026 · Journal of Alzheimer s Disease
  24. Molecular and Transcriptional Signatures of Gray Matter Volume Alterations Associated With Depressive Symptoms in Mild Cognitive Impairment
    Hu Xu, Yang Li, Chensi Li, Fenglin Xu, Yun Liu, Kehan Yan, Shiyi Chen, Wenxiu Song, Yifeng Luo, Yuefeng Li · 2026 · Human Brain Mapping
  25. Associations of plasma sphingomyelin SM (d18:1/24:0) with Alzheimer's disease pathology and cognition in non-demented adults
    Fan Guo, Ze-Hu Sheng, Tao Li, Liang-Yu Huang, Bingyu Li, Xi-Jin Wang, Alzheimer’s Disease Neuroimaging Initiative · 2026 · Journal of Alzheimer s Disease
  26. Longitudinal Associations Between Neurodegenerative Biomarkers and Cognitive Decline in Older Adults: Insights From the LASI ‐ DAD Study
    Abhijith R. Rao, Rashmita Pradhan, Masroor Anwar, Abhishek Gupta, Manjusha Bhagwasia, Emma L. Nichols, Alden L. Gross, Bharat Thyagarajan, Peifeng Hu, Eileen M. Crimmins et al. · 2026 · Journal of the American Geriatrics Society
  27. Multivariate patterns of plasma biomarkers predict region‐specific Alzheimer's pathology and cognitive decline across independent cohorts
    Jafar Zamani, Amirali Vahid, Edward N. Wilson, S. M. Hadi Hosseini, the Frontotemporal Lobar Degeneration Neuroimaging Initiative · 2026 · Alzheimer s & Dementia
  28. Ultrasensitive chemiluminescent detection of plasma Aβ1-40 based on soluble macromolecular signal amplification carrier
    Chao Guo, Meng Liu, Zhanfei An, Shuaipeng Li, Menglin Cui, Jianqi Nie, Yang Sun, Zhonghu Bai · 2026 · Talanta
  29. Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study
    Miquel Massons, Núria Guillén, Jordi Sarto, Neus Falgàs, Sergi Borrego‐Écija, Diana Esteller, Magda Castellvı́, Adrià Tort‐Merino, Agnès Pérez‐Millan, Anna Antonell et al. · 2026 · Annals of Clinical and Translational Neurology
  30. Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer’s disease
    Jehyun Ahn, Jihwan Yun, Michael Walter Weiner, D Shin, Heekyoung Kang, Sohyun Yim, Seonghyeon Kim, Heekyoung Park, H D Jang, Min Young Chun et al. · 2026 · Alzheimer s Research & Therapy
  31. Hypertension acts together with Aβ pathology in late-life to promote memory loss
    Lucas Uglione Da Ros, João Pedro Ferrari‐Souza, Marco Antônio De Bastiani, Lucas Augusto Hauschild, Bruna Bellaver, Pâmela C.L. Ferreira, Douglas Teixeira Leffa, Guilherme Povala, Firoza Zubeida Lussier, Mira Chamoun et al. · 2026 · The Journal of Prevention of Alzheimer s Disease
  32. The Multiple Functions of Amyloid Beta in the Gut Epithelium and the Role of the Microbiota: A Study in the APP/PS1 Animal Model Subjected to Chronic Synbiotic Treatment
    Giorgia Sarti, Giorgio Tognozzi, Giada Magni, Daniele Lana, Francesca Rossi, Chiara Traini, Maria Giuliana Vannucchi · 2026 · Nutrients
  33. Plasmonic nanoplatforms for Alzheimer’s disease biomarker detection: LSPR and SERS strategies toward clinical translation
    Hyejin Chang, Homan Kang, Seung-Ki Lee, Jaehong Lim, Ksenia V. Kastanenka, Satoshi Kashiwagi, Bong‐Hyun Jun · 2026 · Materials Today
  34. Plasma neurofilament light chain and regional brain atrophy mediate the association of neuropsychiatric symptoms with cognition in Alzheimer’s disease: evidence from two population-based studies
    Yayu Wang, Huai-Yuan Zhu, Wei Miao, Zi Wang, Jia-Jia Qin, Xiao-Han Song, Yue-Hua Wang, Zhong-wu Sun, Xia Zhou, Xian-Feng Yu et al. · 2026 · Psychological Medicine
  35. Circulating lipids are related to longitudinal changes of ATN biomarkers for Alzheimer’s disease
    Jun Pyo Kim, Kwangsik T. Nho, Tingting Wang, Kevin Huynh, Matthias Arnold, Shannon L. Risacher, Paula J. Bice, Xianlin Han, Bruce S. Kristal, Colette Blach et al. · 2026 · Molecular Psychiatry
  36. Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease
    Carolin Kurz, Daniela Hattenkofer, Maximilian Pihale-Haug, Anna Hufnagel, Selim Guersel, Matthias Brendel, Boris‐Stephan Rauchmann, Johannes Levin, Günter U. Höglinger, Robert Perneczky · 2026 · Aging Clinical and Experimental Research
  37. Valine modulates Alzheimer’s disease risk in APOE ε4 carriers: evidence from two cohorts
    Ze-Lin Yang, Can Zhang, Shi Tang, Xin-Yu Zhang, Liang-Yu Huang, Lan Tan, Wei Xu · 2026 · Journal of Advanced Research
  38. Role of Machine Learning Algorithms on Alzheimer Disease Prediction
    V. Krishna Kumar, M.S. Geetha Devasena, G. Gopu, N. Sivakumaran · 2022 · Lecture notes in networks and systems
  39. An Experimental Study on Evaluating Alzheimer’s Disease Features using Data Mining Techniques
    Hadeel Albalawi · 2022 · Journal of Information & Knowledge Management
  40. Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
    Franz Felix Konen, Hannah Benedictine Maier, Alexandra Neyazi, Stefan Bleich, Konstantin Neumann, Thomas Skripuletz · 2023 · Neurological Research and Practice
  41. A rat model established by simulating genetic–environmental interactions recapitulates human Alzheimer's disease pathology
    Xiaomei Lin, Tianyuyi Feng, Erheng Cui, Yunfei Li, Zhang Qin, Xiaohu Zhao · 2023 · Brain Research
  42. Recent Advances in Understanding and Managing Alzheimer's Disease: from Pathogenesis to Treatment
    Rafael Leituga de Carvalho Cavalcante, Maurício Samartino, Larissa Abussafi Miranda, Jeniffer da Silva Alencar Mendes, Tatiana de Lima Tanaka, F. Silva, Lucas Monteiro Molina, Bruno Carvalho Diniz, Daniela Alves Dantas, Dhyana Ataide Ferraz Sarges et al. · 2024 · Revista de Gestão Social e Ambiental
  43. Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status
    Daniele Imperiale, Cristiana Atzori, Daniele Pio Angeloro, Amelia Murgioni, Alessia Bagatin, Valentina Secci, Andrea Calcagno, Marco Alfonso Narduc Capobianco, Mario Coletti Moja, Eugenia Rota et al. · 2024 · Journal of Alzheimer s Disease
  44. Comparison of ERlangen Score with pTau/Aβ1-42 Ratio for Predicting Cognitive Decline and Conversion to Alzheimer’s Disease
    JA Schwarz, Pauline Schulz, Janine Utz, Laura Rudtke, Johannes Jablonowski, Neele Klement, Piotr Lewczuk, Johannes Kornhuber, Juan Manuel Maler, Timo Jan Oberstein · 2025 · Brain Sciences
  45. Computational Risk Stratification of Preclinical Alzheimer’s in Younger Adults
    Oriehi Edisemi Destiny Anyaiwe, Nandini Nataraj, Bhargava Sai Gudikandula · 2025 · Diagnostics
  46. Mining relations between neuropsychological data to characterize Alzheimer’s disease
    Germán A. Pabón, Diana L. Giraldo, Eduardo Romero Castro · 2021 · International Symposium on Medical Information Processing and Analysis (SIPAIM)
  47. Basal forebrain activity predicts functional degeneration in the entorhinal cortex and decreases with Alzheimer’s Disease progression
    Marthe Mieling, Martin Göttlich, Mushfa Yousuf, Nico Bunzeck, the Alzheimer’s Disease Neuroimaging Initative · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  48. Evaluation of ATN PD framework and biofluid markers to predict cognitive decline in early Parkinson’s disease
    Katheryn A Q Cousins, David John Irwin, Thomas Francis Tropea, Emma Rhodes, Jeffrey S. Phillips, Alice S. Chen‐Plotkin, Michael C. Brumm, Christopher S. Coffey, Ju‐Hee Kang, Tanya Simuni et al. · 2023 · medRxiv
  49. Genome-wide meta-analysis of CSF biomarkers in Alzheimer’s disease and Parkinson’s disease cohorts
    Michael Ta, Cornelis Blauwendraat, Tarek Antar, Hampton L. Leonard, Andrew Singleton, Mike A. Nalls, Hirotaka Iwaki, Alzheimer’s Disease Neuroimaging Initiative, the Fox Investigation for New Discovery of Biomarkers · 2023 · medRxiv
  50. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
    Matthew D. Howe, Karysa J. Britton, Hannah E. Joyce, William E. Menard, Sheina Emrani, Zachary J. Kunicki, Melanie A. Faust, Brittany C. Dawson, Meghan C. Riddle, Edward D. Huey et al. · 2024 · Research Square
  51. The Impact of Kidney Function on Alzheimer’s Disease Blood Biomarkers: Implications for Predicting Amyloid-β Positivity
    Burak Arslan, Wagner Scheeren Brum, Ilaria Pola, Joseph Therriault, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Kübra Tan, Paolo Vitali, Maxime Montembeault et al. · 2024 · Research Square
  52. Heterogeneous ageing of brain networks across the Alzheimer’s disease continuum
    Yanxi Huo, Weijie Huang, Zhengzhao Liu, Tianyu Bai, Haojie Chen, Yichen Wang, Kexin Wang, Daoqiang Zhang, Jian Cheng, Yuling Sun et al. · 2025 · medRxiv
  53. Performance of Elecsys pTau217 plasma immunoassay to detect brain amyloid pathology
    Derrek P. Hibar, Alina Bauer, Christina Rabe, Niels Borlinghaus, Alexander Jethwa, Gwendlyn Kollmorgen, Annunziata Di Domenico, Henrik Zetterberg, Kaj Blennow, Colin Louis Masters et al. · 2025 · medRxiv
  54. Topographical patterns of whole-brain structural alterations in association with genetic risk, cerebrospinal fluid, positron emission tomography biomarkers of Alzheimer’s disease, and neuropsychological measures
    Albert Dayor Piersson, Mazlyfarina Mohamad, Subapriya Suppiah, Nor Fadilah Rajab · 2021 · Clinical and Translational Imaging
  55. Diagnosi clinicolaboratoristica della malattia di Alzheimer
    Julien Lagarde, Pauline Olivieri, Michel Bottlaender, Marie Sarazin · 2021 · EMC - Neurologia
  56. Polygenic effect on accelerated tau pathology accumulation in Alzheimer’s disease: implications for patient selection in clinical trials
    Anna Rubinski, Simon Frerich, Rainer Malik, Nicolai Franzmeier, Alfredo Ramı́rez, Martin Dichgans, Michael Ewers, Alzheimer’s Disease Neuroimaging Initiative · 2021 · medRxiv
  57. Комплексный метод анализа геометрической точности цилиндров в процессе сборки судовых малоразмерных дизелей
    Яхьяев Насреддин Яхьяевич, Nurulla M. Vagabov · 2009 · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES
  58. Conjunto de pruebas para los servicios de Google Maps
    Santos Baldó, Damián Antonio · 2015
  59. Peer Review #1 of "Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort (v0.1)"
    2020 · PeerJ
  60. Development of Fluid Biomarkers for Alzheimer’s Disease
    Kaj Blennow · 2022 · Cambridge University Press eBooks
  61. Peer Review #2 of "Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort (v0.2)"
    2020 · PeerJ
  62. Faculty Opinions recommendation of Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts.
    Ralph E. Mistlberger, Brianne A. Kent · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  63. Peer Review #2 of "Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort (v0.1)"
    2020 · PeerJ
  64. Can we improve prediction of Alzheimer's disease and Mild Cognitive Impairment by combining MMSE score and MRI-based imaging data?
    Anna Marcisz, Joanna Polańska · 2022 · Research Square
  65. CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuum
    Qiang Qiang, Loren Skudder‐Hill, Tomoko Toyota, Zhe Huang, Wenshi Wei, Hiroaki Adachi · 2022 · Research Square
  66. Exploring the intricacies and pitfalls of the ATN framework: An assessment across cohorts and thresholding methodologies
    Yasamin Salimi, Daniel Domingo‐Fernándéz, Martin Hofmann‐Apitius, Colin J. Birkenbihl, the Alzheimer’s Disease Neuroimaging Initiative, the Japanese Alzheimer’s Disease Neuroimaging Initiative, the Alzheimer’s Disease Repository Without Borders Investigators · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  67. CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuum
    Qiang Qiang, Loren Skudder‐Hill, Tomoko Toyota, Zhe Huang, Wenshi Wei, Hiroaki Adachi · 2022 · Research Square
  68. DEVELOPING A DATA MINING BASED EFFICACIOUS PREDICTION MODEL OF DIABETICS AND AILED AILMENTS
    Shreyansh Balhara · 2022 · International Journal of Research in Medical Sciences & Technology
  69. Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer’s Disease Continuum
    Jane K. Stocks, Ashley Heywood, K. Popuri, M. Beg, H. Rosen, Lei Wang · 2023 · Journal of Alzheimer's Disease
  70. DEVELOPING AN EFFECTIVE MACHINE LEARNING ALGORITHM SYSTEM IN THE EARLY DETECTION AND DIAGNOSIS OF ALZHEIMER’S DISEASE
    Anoushka Mongia · 2021 · International Journal of Research in Medical Sciences & Technology
  71. The potential of extracellular vesicle lipid profiling in Alzheimer's disease.
    Huaqi Su, Colin Louis Masters, Ashley Ian Bush, Kevin Jeffrey Barnham, Gavin E. Reid, Laura J. Vella · 2023
  72. BDNF Val66Met moderates increases in CSF t-tau and p-tau181 in early sporadic Alzheimer’s disease: A prospective cohort study
    Diny Thomson, Emily Rosenich, Paul T. Maruff, Yen Ying Lim · 2023 · Research Square
  73. Influence of liver function markers and apolipoprotein E ε4 on pathogenesis and cognitive decline in Alzheimer’s disease
    Sang‐Won Han, Sang‐Hwa Lee, Jong Ho Kim, Jaejun Lee, Young Ho Park, SangYun Kim, Kwangsik T. Nho, Jong‐Hee Sohn · 2023 · Research Square
  74. Predicting MCI and Alzheimer’s disease on structural brain integrity with machine learning
    Marthe Mieling, Mushfa Yousuf, Nico Bunzeck · 2023
  75. Exploring anatomical brain heterogeneity in subjects with mild cognitive impairment
    Germán A. Pabón, Diana L. Giraldo, Eduardo Romero · 2023 · International Symposium on Medical Information Processing and Analysis (SIPAIM)
  76. Relationship between astrocytic reactivity and white matter integrity in the context of Alzheimer’s disease pathologies
    Feng Vankee Lin, Oceanna Yueran Li, Sarah Therrien, Adam G. Turnbull · 2024 · Research Square
  77. Ophthalmology Perspective on The Theory of Amyloid Beta Toxicity: Implications on Future Studies
    Saif Aldeen AlRyalat, Mohammad Ali Alshrouf, Abdulla AlMomani, Abdee Tawfiq Ryalat · 2024 · High Yield Medical Reviews
  78. Fast Declining Prediction in Alzheimer’s Disease from Early Clinical Assessment
    Lourdes Álvarez‐Sánchez, Mar Peretó, Lorena García, Ángel Balaguer, Carmen Peña‐Bautista, Laura Ferré‐González, Miguel Baquero, Consuelo Cháfer-Pericas · 2024 · Current Neuropharmacology
  79. Polygenic Risk Scores are Associated to Aβ-τ Protein Accumulation in Alzheimer's Disease
    Irene Treccani, Giorgio Dolci, Lorenza Brusini, Federica Cruciani, Ilaria Boscolo Galazzo, Gloria Menegaz · 2024 · IEEE International Conference on Metrology for eXtended Reality, Artificial Intelligence and Neural Engineering (MetroXRAINE)
  80. Integrated Gradients Demystified: An MRI Case Study on Aβ-T Protein Localization
    Giorgio Dolci, Cristian Morasso, Federica Cruciani, Lorenza Brusini, Lorenzo Pini, Vince D. Calhoun, Ilaria Boscolo Galazzo, Gloria Menegaz · 2024 · IEEE International Conference on Metrology for eXtended Reality, Artificial Intelligence and Neural Engineering (MetroXRAINE)
  81. Temporal modeling and AT profiles in the early phase of Alzheimer's disease
    Carlos A. Platero · 2025 · Journal of Alzheimer s Disease Reports
  82. The calcium channel blocker Cav2.1 combined with amyloid beta monoclonal antibodies may reduce the occurrence of ARIA-E
    Dinghao An, Xiaotong Li, Yang Y. Xu · 2025 · Medical Hypotheses
  83. New Research on Biomarkers in Alzheimer’s Continuum
    Immacolata Vecchio, Carmela Colica · 2025 · Reviews on Recent Clinical Trials
  84. A century of Alzheimer's disease: Merging neuropathology with in vivo biomarkers
    Theresa M. Harrison, William J. Jagust · 2025 · Elsevier eBooks
  85. Cerebrospinal fluid Visinin-like protein-1 was associated with the relationship of body mass index with Alzheimer’s disease pathology and cognition in non-demented elderly
    Yayu Wang, Siqi Yu, Man Zhang, Huaiyuan Zhu, Suhuan Chen, Yajun Zhou, Xia Zhou, Zhongwu Sun, Xianfeng Yu, Xiaoqun Zhu et al. · 2025 · Journal of Alzheimer s Disease Reports
  86. Predicting cognitive change using functional, structural, and neuropsychological predictors
    Laurie Décarie-Labbé, Samira Mellah, Isaora Zefania Dialahy, Pierre Bellec, Sylvie Belleville, Christian Bocti, Frédéric Calon, Howard Mark Chertkow, D. Louis Collins, Stephen C. Cunnane et al. · 2025 · Brain Communications
  87. The complementary role of automated brain volumetry to stratify ADNI participants within the ATN framework
    Ilaria Ricchi, Alessandra Griffa, Ricardo A. Corredor Jerez, Jonas Richiardi, Jean‐François Démonet, Gilles Allali, Bénédicte Maréchal, Olivier Rouaud, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Journal of Alzheimer s Disease
  88. Association of Brain and Ventricular Boundary Shift Integral Measurements with CSF Biomarkers: A Case-Control Study
    Seyedeh Fahimeh Hosseini, Parastoo Akbarabadi, Fatemeh Noorani, Danial Kazemi, Hamidreza Sadeghsalehi, Mohammadtaghi Fattahpour, MohammadHosein Sheybani‐Arani, Masoud Noroozi, Ali Kazemi, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Current Alzheimer Research
  89. Neural network-enhanced investigation of ferroptosis and druggability in early-onset alzheimer’s disease
    Pratibha Singh, Soumya Lipsa Rath · 2026 · Metabolic Brain Disease
  90. Imaging Markers of Amyloid and Tau in Alzheimer Disease
    Rawan M. Tarawneh · 2025 · Springer eBooks
  91. Evaluating the Predictive Value of Oxylipins for Cognitive Measures and White Matter Hyperintensities in Alzheimer’s Disease Continuum Compared to Conventional Beta‑amyloid and Tau Protein Biomarkers
    Alireza Shaabanpoor Haghighi, Mahsa Mayeli, Elham Ramezannezhad, Negin Pouroushaninia, Rezvan Barzegar Parizi, Mahtab Nourollahi-Foumeshi, Nasim Idelkhani, Zahra Dadjou, Niloofar Saeedipour, Negar Safaee et al. · 2025 · Molecular Neurobiology
  92. Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays
    Joyce Ruifen Chong, Abdul Hye, Merçé Boada, Per Svenningsson, Tormod Fladby, Dag Aarsland · 2025 · Journal of Alzheimer s Disease
  93. Understanding the Silent Threat: A Review to Neurodegenerative Disorders
    Amita Kajrolkar · 2025 · Premier Journal of Neuroscience
  94. Amygdala subregional atrophy across ATN-defined Mild Cognitive Impairment subgroups
    Qianqian Yuan, Darui Zheng, Wenzhang Qi, Xuhong Liang, Yiming Ruan, Yue Tang, Chen Xue, Chaoyong Xiao · 2026 · Frontiers in Neuroscience
  95. Elevated serum β-synuclein predicts cognitive decline and progression to dementia
    Nayeong Kong, Joon Hyung Jung · 2025 · Journal of Neurology Neurosurgery & Psychiatry
  96. Associations Between Polygenic Risk for Alzheimer’s Disease and Grey Matter Volume Are Dependent on APOE, Pathological and Diagnostic Status
    Valerio Nocella, Riccardo Manca, Annalena Venneri · 2025 · Genes
  97. Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson’s Disease: Cognitive–Affective Dissociation with Specificity for Tau
    João Paulo Mota Telles, Lucas Camargo, Anna Carolyna Gianlorenço, Felipe Fregni · 2025 · Biomedicines
  98. Hippocampal grey matter changes across scales in Alzheimer’s Disease
    Bradley G. Karat, Mahdieh Varvani Farahani, Malcolm Davidson, Arun Thurairajah, Alaa Taha, Taylor W. Schmitz, ALI RAZA KHAN, Alzheimer’s Disease Neuroimaging Initiative · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  99. Hiérarchisation des biomarqueurs pour le diagnostic des pathologies neurodégénératives : application à la maladie d’Alzheimer
    Aurélie Kas, Stéphanie Bombois · 2025 · Médecine Nucléaire
  100. Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis
    Nils Richter, Oezguer A. Onur, Gereon R. Fink, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Alzheimer s Research & Therapy